Salivary in Medical Technology

Is Obesity an Oral Bacterial Disease?

... D. Groppo, S. Halem and E. Carpino measured salivary bacterial populations of overweight women. Saliva ... overweight women. Classification tree analysis of salivary microbiological composition revealed that 98.4 ... at levels greater than 1.05 percent of the total salivary bacteria. Analysis of these data suggests that ...

Dry Mouth Linked to Prescription and Over the Counter Drugs

... or xerostomia , is caused by a decrease in salivary function. It affects approximately one in four ... contributor to dry mouth. Aging, dehydration and salivary gland disease were also cited as major ... percent report that patients attempt to increase salivary production by drinking water; less than 58 ...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

... of a statistically significant increase in salivary flow production compared to placebo at all three ... possibly other conditions in which a reduction in salivary flow has been observed such as the effects of ... dosing. For the primary endpoint, whole mouth salivary flow was collected by passive drainage into ...

TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia

... receptor stimulation as measured by increases in salivary flow. A total of 60 healthy males, between the ... In the study, increases in peak and total salivary flow were detected for NGX267 in comparison to ... with peak plasma levels of NGX267. Decreased salivary flow results in dry mouth, or xerostomia, and is ...

Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth

... active drug, physostigmine, a cholinesterase inhibitor, targets the minor salivary glands with a direct local action, inducing a more lubricating saliva. In ... inhibitor physostigmine, which has been shown to effectively increase salivary flow. Unlike systemically administered drugs, the local route of ...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)

... akathisia (ABILIFY 10 mg: 8.2%; ABILIFY 30 mg: 11.1%; placebo: 2.1%) and salivary hypersecretion (ABILIFY 10 mg: 3.1%; ABILIFY 30 mg: 8.1%; placebo: 0%). ... nausea (11% vs 4%), akathisia (10% vs 2%), blurred vision (8% vs 0%), salivary hypersecretion (6% vs 0%), and dizziness (5% vs 1%) -- Adult ...

Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients

... product Xalieve(TM) is a locally administered formulation of the cholinesterase inhibitor physostigmine, which has been shown to effectively increase salivary flow. The company is part of the Karolinska Development AB portfolio. For more information, please visit http://www.calabar.se Contact: VP ...

CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation

... of chemoradiation-induced oral mucositis." Oral Mucositis: A Common and Debilitating Condition Oral complications including mucositis and salivary gland dysfunction are common and often debilitating side effects of cancer therapy. OM is estimated to affect more than 400,000 cancer patients each ...

Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment

... is a chronic disorder that occurs when a person's normally protective immune system attacks and destroys moisture-producing glands, including the salivary and tear glands. There are currently no specific topical pharmaceutical medications to alleviate the symptoms of dry mouth associated with Sjogren's ...

Study Finds Starion Instruments' Tissue Welding Technology Safe and Effective in Parotidectomy Procedures

... The researchers reviewed records for operative times, estimated blood loss and postoperative complications of bleeding, facial nerve paresis, salivary fistula, and gustatory sweating, and compared these results with previous reports using other parotid dissection techniques. With Starion's ...

TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds

... doses of NGX267 in three Phase I trials involving healthy volunteers. In two of these studies, statistically significant increases in salivary flow were demonstrated. Expand Business Development Initiatives Across Pipeline The company will evaluate partnership opportunities for ...

Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

... mucosal surfaces in the head and neck area such as the mouth, tongue, tonsils, throat and voicebox. The term encompasses cancers of the oral cavity, salivary glands, paranasal sinuses and nasal cavity, pharynx, larynx, and lymph nodes in the upper part of the neck. "Head and neck cancer is particularly ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... (any grade) was higher with ERBITUX in combination with radiation therapy compared with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... in 2007, including cancers of the tongue, the rest of the mouth, the salivary glands and inside the throat, the voice box, eye and orbit, thyroid and ... with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... in 2007, including cancers of the tongue, the rest of the mouth, the salivary glands and inside the throat, the voice box, eye and orbit, thyroid and ... with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous ...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

... (any grade) was higher with ERBITUX in combination with radiation therapy compared with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain (11%/9%), ...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

... (any grade) was higher with ERBITUX in combination with radiation therapy compared with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain (11%/9%), ...

Pacgen Announces Positive Results from Phase I/II Trial of Novel Antifungal Drug

... Board PAC-113 is a peptide based anti-fungal drug candidate targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction. The Phase I/II clinical trial of PAC-113 was conducted at sites in the United States and South Africa and recruited over 100 HIV ...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

... (any grade) was higher with ERBITUX in combination with radiation therapy compared with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain (11%/9%), ...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

... (any grade) was higher with ERBITUX in combination with radiation therapy compared with radiation therapy alone. The following sites were affected: salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue (49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin (42%/33%), brain (11%/9%), ...